Equity Analysis /
United States of America

US : Galmed Pharmaceuticals Ltd. - GLMD | 3Q21 Update: Open Label Data Suggests Greater Anti-fibrotic Response Possible With BID Dosing

    Contributors
    Timur Ivannikov
    Ryan Deschner
    CGS-CIMB
    8 November 2021
    Published by